The development of endometrial hyperplasia in aged PD-1-deficient female mice by Guoning Guo et al.
Guo et al. Diagnostic Pathology 2014, 9:97
http://www.diagnosticpathology.org/content/9/1/97RESEARCH Open AccessThe development of endometrial hyperplasia in
aged PD-1-deficient female mice
Guoning Guo1, Hong Li2, Dayan Cao3 and Yongwen Chen3*Abstract
Background: Programmed death-1 (PD-1, Pdcd1)-deficient mice develop different types of autoimmune diseases
depending on the mouse strain but its role in uterus development has not been reported.
Methods: In this study, the expression of PD-1 and its ligands, PD-L1 and PD-L2, in uterine tissues from aged WT
mice in a 129svEv-Brd background was analyzed by immunohistochemistry and the uterine morphology between
WT and PD-1-/- mice was compared by hematoxylin and eosin staining.
Results: The aged PD-1-/- female mice in a 129svEv-Brd rather than Balb/c background develop endometrial hyperplasia.
H&E staining showed an increase in the number of glands, neovascularization and an extremely large luminal cavity in
aged PD-1-/- uteri. Immunohistochemical assay showed that the expression of PD-1 was observed in glandular/luminal
epithelium and cells infiltrating the stroma. Fluorescent double staining demonstrated that PD-1 expresses on CD68+
macrophages, CD3+ T cells, CD16+ monocytes, CD56+ NK cells and CK-18+ epithelial cells, respectively. Additionally, PD-1
co-expresses with vascular endothelial growth factor (VEGF), and PD-1 deficiency resulted in an accumulation of
glandular/luminal epithelium derived VEGF, which accelerates the expression of the proliferation-associated protein,
proliferating cell nuclear antigen (PCNA), and thus potentially lead to epithelial proliferation in aged PD-1-/- uteri.
Conclusions: These findings showed that PD-1 deficiency augments luminal epithelial cell proliferation probably through
induced VEGF secretion, suggesting PD-1 plays an important role in controlling the growth and differentiation of the
uterine epithelium.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
5809067461223905
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Co-signaling by B7/CD28 family members regulates the
initiation, maintenance, and termination of immune re-
sponses. Programmed death-1 (PD-1) is an inhibitory re-
ceptor expressed on activated T cells, B cells and myeloid
cells [1]. PD-1 deficiency (PD-1-/-) causes lupus-like glom-
erulonephritis and arthritis in C57BL/6 mice [2,3], auto-
immune dilated cardiomyopathy (DCM) and gastritis in
BALB/c mice [4,5], acute type 1 diabetes mellitus (T1DM)
in nonobese diabetic (NOD) mice [6], and lethal myocar-
ditis in MRL mice [7]. In humans, polymorphisms in the
PD-1 gene have been associated with susceptibility to* Correspondence: yongwench@163.com
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unless otherwise stated.systemic lupus erythematosus [8], type I diabetes [9], mul-
tiple sclerosis [10], and rheumatoid arthritis [11]. Add-
itionally, PD-1-/- mice in a 129svEv-Brd background were
also more susceptible to the development of experimental
autoimmune encephalomyelitis (EAE) [12]. Nevertheless,
the organ development regulated by PD-1 signal is still
under investigation.
PD-L1 (B7-H1) and PD-L2 (B7-DC), two immunoregula-
tory molecules belonging to the B7 family, were identified
as the ligands for PD-1 [13,14]. The expression of PD-L1
has been detected not only in lymphoid organs but also in
nonlymphoid tissues and was enhanced in several types of
tumor cells under inflammation conditions, suggesting that
PD-L1 might regulate lymphocyte function at sites of in-
flammation [15]. The expression of PD-L2, however, was. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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monocytes and T cells [16].
The expression, anatomic distribution and potential
role for PD-1/PD-Ls in uterine development have not
been investigated. We here showed that aged PD-1-
deficient female mice in a 129svEv-Brd background de-
velop endometrial hyperplasia. This effect potentially
reflects the induction VEGF secretion from epithelial
cells upon PD-1 signaling deficiency.
Methods
Ethics statement
All experiments were approved and conducted in accord-
ance with the guidelines of the Animal Care and Use
Committee of the Third Military Medical University. All
efforts were made to minimize animal suffering.
Mice
PD-1-deficient mice (Background: 129svEv-Brd) were
kindly provided by Dr. Laura L. Carter (Inflammation
Department, Wyeth Research, Cambridge, MA, USA).
Prof. T. Honjo (Department of Immunology and Gen-
omic Medicine, Kyoto University, Japan) kindly gave us
the PD-1-KO-N10 mice (strain: BALB/cJ). The WT con-
trol mice were purchased from the Animal Center of
Beijing University School of Medicine. All mice were
maintained in micro-isolator cages and housed in the
animal colony at the Animal Center, Third Military
Medical University, and standard laboratory chow diet
and water was supplied.
Histology and immunohistochemistry
Section were used to detect the indicted protein expres-
sion with using the following primary antibodies: anti-
PD-L1 (2.5 μg/ml, Catalog#: AF1019, R&D Systems),
anti-PD-L2 (2.5 μg/ml, Catalog#: AF1022, R&D Sys-
tems), anti-PD-1 (2 μg/ml, Catalog#: AF1021, R&D Sys-
tems) and anti-VEGF (1:100, clone: C-1, Santa Cruz). A
previously published protocol for immunohistochemistry
was used [17].
Immunofluorescent double staining
For immunofluorescent double staining, the sections were
incubated with mouse monoclonal anti-PD-1 and anti-
VEGF antibodies at 4°C overnight. After washing with PBS
(3x5-min incubations), sections were incubated with Alexa
568-conjugated goat anti-mouse IgG antibodies (Jackson
ImmunoResearch, West Grove, PA, USA) for 1 h. Sections
were subsequently further incubated with anti-CD3 (1:50,
Abcam), anti-CD56 (1: 150, Santa Cruz), anti-CK-18 (1:
150, clone: H-80, Santa Cruz), anti-CD68 (1: 200, clone: H-
255, Santa Cruz) antibodies at 4°C overnight and incubated
with fluorescent isothiocyanate-conjugated goat anti-mouse
IgG antibodies (Jackson ImmunoResearch) for anadditional 1 h. Subsequently, the sections were incubated
with 1 μg/ml 4′,6-diamidino-2-phenylindole (DAPI, Sigma,
CA, USA) for 10 min to stain the nuclei. Sections incubated
with the appropriate isotype control primary antibodies and
fluorescently labeled secondary antibodies were used as
negative controls.
Cell count and statistical analysis
The proportion of PCNA-positive nuclei in the glandular
epithelium was determined through image analysis of the
histological sections. Photomicrographs were captured
and analyzed using Image Pro-Plus 5.0 software (Media
Cybernetics, Silver Spring, MD) [18]. The number of
PCNA+ nuclei per high-power field was counted. The data
were analyzed using GraphPad Prism 4.03 software. An
unpaired Student t test (two-tailed) was used to assess
comparisons of PCNA+ nuclei between PD-1-/- and WT
uteri. A p value <0.05 was considered statistically signifi-
cant different.
Results
Changes in the gross anatomy and morphology of the
uteri in aged PD-1-/- female mice
The WTand PD-1-/- mice at different ages were sacrificed,
and the morphology of several organs was compared. An
interesting finding is the uteri from PD-1-/- female mice in
the 129svEv-Brd rather Balb/c background are much lar-
ger than that of the WT littermates at 2, 2.5 and 3 years
of age (Figure 1B and C), indicating that the aged PD-
1-/- female mice developed endometrial hyperplasia.
Nevertheless, the uteri from young (for example, 1-
year-old) PD-1-/- and WT mice in 129svEv-Brd back-
ground were comparable (Figure 1A). H&E staining
showed that there were numerous glands (Figure 1E) and
neovascularizations (Figure 1F) in the aged PD-1-/- uteri
(129svEv-Brd background), as compared to WT controls
at 2 years of age (Figure 1D). These findings suggested that
endometrial hyperplasia was developed in aged PD-1-/- fe-
male mice in a 129svEv-Brd background.
PD-1 deficiency resulted in epithelial cell proliferation
To analyze the pathogenesis of endometrial hyperplasia
in aged PD-1-/- female mice, the expression of the
proliferation-associated protein, proliferating cell nuclear
antigen (PCNA), was analyzed in aged uteri between PD-
1-/- and WT mice in 129svEv-Brd background. Immuno-
fluorescent staining revealed the presence of PCNA+ cells
in the uteri, and PCNA expression was primarily detected
in luminal/glandular epithelium (Figure 2A). The PCNA+
nuclei were counted and results showed that 42.1 ± 3.2% of
luminal/glandular epithelial cells in PD-1-/- uteri were posi-
tive for PCNA, while only 21.4 ± 1.2% of the cells in WT
uteri showed nuclei positive for PCNA (Figure 2B),
Figure 1 Gross anatomic and histological comparison of uteri between PD-1-/- and WT mice. Gross anatomy of uteri between PD-1-/- and
WT mice (129svEv-Brd background) at (A) 1 year and (B) 2 years of age, results showed that uteri from PD-1-/- mice in 2-year old are more larger
than WT littermates. One of represents five mice was shown. (C) Gross anatomy of uteri from PD-1-/- and WT mice on Balb/c background at
2-year age was compared, results showed that uteri from PD-1-/- mice were similar to than from WT littermates. One of represents five mice was
shown. Histology of uteri from WT (D) and PD-1-/- mice (E and F) in a 129svEv-Brd background at 2-year age was compared by using H&E
staining. Star indicated glands and arrow showed neovascularization; D-F, Scale bar = 20 μm; N = 5 of each group.
Figure 2 Enhanced PCNA positive cells in PD-1-/- uteri was measured by immunofluorescent staining. Uteri from 2-year old PD-1-/- and
WT mice were selected to detect the expression of PCNA by immunofluorescent staining (A). LE: luminal epithelium; S: stroma. The blue color
indicates nuclear staining with 4′,6-diamidino-2-phenylindole (DAPI). Scale bar = 20 μm. N = 4 of each group. (B) The PCNA-positive nuclei in
uterine tissues between PD-1-/- and WT mice were counted and compared. *p < 0.05.
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liferation in the aged uteri.
Detection and localization of PD-1 and its ligands in the
aged uteri
We further analyzed the expression of PD-1 and its ligands,
PD-L1 and PD-L2 in uteri of aged WT mice (129svEv-Brd
background). Immunohistochemistry revealed that PD-1
protein was expressed in glandular and luminal epithelium
(Figure 3B). However, uterine sections from aged PD-1-/-
mice incubated with anti-mouse PD-1 antibodies were ab-
sence PD-1 expression (Figure 3A). Some cells infiltrated in
stroma were also positive for PD-1 (Figure 3C). Immuno-
fluorescent labeling showed PD-1 was presence on CD68+
macrophages, CD3+ T cells, CD16+ monocytes, CD56+
NK cells and CK-18+ epithelial cells, but it was absent on
CD31+ endothelial cells (Figure 3D).
The expression of the PD-1ligands, PD-L1 and PD-L2,
in the aged uteri from WT mice was also detected by im-
munohistochemistry. Similar to PD-1, the expression ofFigure 3 The characteristic and anatomic distribution of PD-1 protein
and immunofluorescent double staining. Uteri from 2-year old PD-1-/-
Immunohistochemistry. (A) Uteri from 2-year old PD-1-/- mice showed n
PD-1-positive cells were observed in glandular/luminal epithelium (B) an
*indicates the luminal cavity and the arrows indicate positive cells infiltr
that PD-1 was expressed on CD68+ macrophages, CD3+ T cells, CD16+ m
expression was absence on CD31+ endothelial cells. The blue color indic
arrows indicate positive cells. Scale bar = 20 μm. N = 4 of each group.PD-L1 was also observed in glandular/luminal epithelium
(Figure 4B). Cells infiltrating the stroma and some endothe-
lial cells were also positive for PD-L1 (Figure 4C). In contrast,
the expression of PD-L2 was absent in blood endothelium
(Figure 4D) but present in glandular/luminal endothelium
and cells infiltrating the stroma (Figure 4E and F).
Augmented VEGF secretion in uteri from aged PD-1
deficient mice
To analyze the potential molecular mechanism for epithe-
lial cell proliferation in aged PD-1-/- uteri, the expression
of VEGF, a growth factor essential for cell proliferation
and uterine growth, was compared between uteri from
PD-1-/- and WT mice in 2 years old. Immunohistochemis-
try showed that the expression of VEGF was slightly de-
tected in uteri from WT mice (Figure 5B). However,
strong VEGF expression was observed in uteri from aged
PD-1-/- female mice, and the expression was primarily ob-
served in the luminal epithelium and cells infiltrated in
stroma (Figure 5C). Immunofluorescent labeling showedin uteri from WT mice was detected by immunohistochemistry
and WT mice were selected to detect the expression of PD-1 by
o positive staining; However, uteri from 2-year old WT mice showed
d filtrating the stroma (C),▲indicates the glandular epithelium;
ating the stroma. (D) immunofluorescent double staining showed
onocytes, CD56+ NK cells and CK-18+ epithelial cells, but PD-1
ates nuclear staining with 4′,6-diamidino-2-phenylindole (DAPI),
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to it expresses on CD68+ macrophages, CD3+ T cells,
CD16+ monocytes, CD56+ NK cells and CK-18+ epithelial
cells (Figure 5D). These results suggest that PD-1 defi-
ciency likely stimulates luminal epithelial cell proliferation
through induced VEGF secretion.
Discussion
The disruption of the PD-1 signal leads to the break-
down of peripheral tolerance and the initiation of auto-
immunity like dilated cardiomyopathy. This effect is due
to PD-1 negatively controls T cell receptor (TCR) signal-
ing [19]. Recently, it was shown that PD-1 deficiency accel-
erates microRNA-21 (miR-21) overexpression, thus lead to
cell proliferation through the enhanced expression of pro-
grammed cell death 4 (PDCD4) [20]. Here, we provided the
first evidence that endometrial hyperplasia was developed
in aged PD-1-/- female mice in a 129svEv-Brd rather than
Balb/c background (Figure 1B), suggesting PD-1 plays anFigure 4 The characteristic and anatomic distribution of PD-1 ligands
by immunohistochemistry. (A) Mouse IgG1 isotype control antibodies sh
the glandular/luminal epithelium; (C) PD-L1 positive cells were observed in
was absent in blood capillary; (E) The PD-L2 positive cells were observed in
observed infiltrating the stroma. ▲ indicates the glandular epithelium; *ind
indicate positive endothelial cells and arrow head showed infiltrated cells t
each group.important role in the growth and differentiation of the
uterine epithelium in129svEv-Brd mice. Our results fur-
ther reflect that the development of disease mediated by
PD-1 signals in animal models is strain restricted.
The expression of PD-1 has been reported on Tcells, nat-
ural killer T cells, B cells and monocytes, and this expres-
sion was enhanced through stimulation with inflammatory
factors, such as TNF-α and IFN-γ. However, PD-L1 and
PD-L2, the two PD-1ligands, shows different expression
patterns [21]. Here, we showed that the expression of
PD-1 was observed on glandular and luminal epithelium
(Figure 3B) and cells infiltrated in stroma (Figure 3C).
Additionally, PD-1 was also detected to be expressed on
CD68+ macrophages, CD3+ T cells, CD16+ monocytes,
CD56+ NK cells and CK-18+ epithelial cells, but it was
absent on CD31+ endothelial cells, as detected by im-
munofluorescent double staining (Figure 3D). Addition-
ally, the expression of PD-L1 and PD-L2 was also detected
on luminal epithelium and infiltrating cells within the aged, PD-L1 and PD-L2, in uteri from 2-year old WT mice was detected
owed no positive staining; (B) PD-L1 positive cells were observed in
the endothelium and cells infiltrated stroma; (D) The PD-L2 expression
the glandular/luminal epithelium; and (F) PD-L2 positive cells were
icates the luminal cavity; ◆ indicated blood capillary. The arrows
hat are positive for PD-L1 or PD-L2. Scale bar = 20 μm. N = 4 of
Figure 5 The characteristic and anatomic distribution of VEGF in uteri from 2-year old WT and PD-1-/- mice. Immunohistochemistry
detection showed (A) no mouse positive staining using IgG isotype control antibodies; (B) the VEGF-positive cells were weakly observed in the
glandular/luminal epithelium of WT uteri; (C) Strong VEGF-positive staining was observed in the glandular/luminal epithelium from PD-1-/- uteri.
▲ indicates the glandular epithelium; *indicates the luminal cavity and arrows showed the positive cells; (D) immunofluorescent double staining
showed that VEGF is expressed on CD3+ T cells, CD56+ NK cells, CK-18+ epithelial cells, CD68+ macrophages and PD-1+ cells. The blue color indicates
nuclear staining with 4′,6-diamidino-2-phenylindole (DAPI), and arrows showed the positive cells. Scale bar = 20 μm. N = 4 of each group.
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tion (Figure 1F) and higher level of PCNA+ cells were seen
in aged PD-1-/- uteri, suggesting strong cell proliferation is
in progress in PD-1-/- uteri (Figure 2). These combine data
suggest that local PD-1/PD-Ls signal probably controls
glandular/luminal epithelial biofunction, like cell prolif-
eration and neovascularization. Indeed, the expression
of PD-1 on the tubular epithelium of murine Adriamy-
cin nephropathy (AN) has been reported previously,
and blockade of PD-1 worsened progressive renal histo-
pathological and functional injury in murine AN [22].
Taken together, our results suggested that PD-1 is not only
expressed on immune cells but also on nonlymphoid tis-
sues, and uterine local PD-1/PD-Ls signal probably dir-
ectly inhibits glandular/luminal epithelial cell proliferation
and neovascularization.
To analyze other potential molecular mechanisms that
involve in the growth and differentiation of the uterine
epithelium in aged PD-1-/- mice, the secretion of VEGF,
which stimulate endothelial and epithelial cell proliferation
through its receptor, VEGFR, was compared in aged uteri
between PD-1-/- and WT mice. An interesting finding is
that glandular/luminal epithelium derived-VEGF in aged
uteri from PD-1-/- mice was augmented dramatically
(Figure 5C), thereby potentially promotes cell proliferationvia its receptor VEGFR and thus resulted in accelerating
neovascularization (Figure 1F). Additionally, VEGF in uteri
was also co-expresses with PD-1 (Figure 5D), suggesting
that PD-1 signaling inhibits epithelial cell proliferation po-
tentially through a reduction of VEGF secretion, in addition
to direct prevents epithelial proliferation by cross-reacts
with PD-Ls. However, the expression of PTEN, a tumor
suppress gene, were significantly higher in cyclical endo-
metrium than in atypical hyperplasia and endometrioid
carcinoma, indicated that PTEN involves in the pathogen-
esis of endometrial hyperplasia [23]. On the other hand,
CyclinD1, a cell -cycle regulator, exhibited a promising po-
tential to predict the prognosis of patients with endometrial
carcinoma [24]. Whether the transcription of PTEN or
CyclinD1 is also controlled by PD-1/PD-Ls need further
investigation.
Conclusion
PD-1 deficiency augments luminal epithelial cell prolifera-
tion and neovascularization in aged uteri, suggesting that
PD-1 plays an important role in the organization, growth
and differentiation of the uterine epithelium.Competing interests
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